Literature DB >> 2189505

Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia.

I Touw1, K Pouwels, T van Agthoven, R van Gurp, L Budel, H Hoogerbrugge, R Delwel, R Goodwin, A Namen, B Löwenberg.   

Abstract

We investigated the proliferation-inducing effects of human recombinant interleukin-7 (IL-7) on acute lymphoblastic leukemia (ALL) cells. It is shown that IL-7 stimulates DNA synthesis in ALL cells of B-cell precursor (n = 5) as well as immature T-cell origin (n = 2). Cytogenetic analysis of the cells of four patients proliferating in IL7-supplemented cultures established the leukemic descendence of the IL-7-responsive cells. 125I-IL-7 binding experiments with the cells of one patient and with two ALL cell lines showed the presence of two types of IL-7 receptors: one with a high affinity (kd 29 to 51 pmol/L) and one with a low affinity (kd 2.3 to 76 nmol/L) for the ligand. We conclude that IL-7 is one of the cytokines involved in the complex regulation of ALL cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189505

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.

Authors:  Xiaoyan Zhang; Huaijun Tu; Yazhi Yang; Xiaoyan Jiang; Xianliang Hu; Qidong Luo; Jian Li
Journal:  J Biol Chem       Date:  2019-06-24       Impact factor: 5.157

2.  IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.

Authors:  Sara González-García; Marta Mosquera; Patricia Fuentes; Tiziana Palumbo; Adela Escudero; Antonio Pérez-Martínez; Manuel Ramírez; Anne E Corcoran; Maria L Toribio
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

3.  Optimal interleukin-7 receptor-mediated signaling, cell cycle progression and viability of T-cell acute lymphoblastic leukemia cells rely on casein kinase 2 activity.

Authors:  Alice Melão; Maureen Spit; Bruno A Cardoso; João T Barata
Journal:  Haematologica       Date:  2016-07-28       Impact factor: 9.941

4.  Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.

Authors:  Geoffrey L Uy; Yen-Michael S Hsu; Amy P Schmidt; Wendy Stock; Theresa R Fletcher; Kathryn M Trinkaus; Peter Westervelt; John F DiPersio; Daniel C Link
Journal:  Leuk Res       Date:  2015-10-01       Impact factor: 3.156

5.  Frequent expression of IL-7 gene transcripts in tumor cells of classical Hodgkin's disease.

Authors:  H D Foss; M Hummel; S Gottstein; K Ziemann; B Falini; H Herbst; H Stein
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

6.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Authors:  Valerie I Brown; Junjie Fang; Keith Alcorn; Rosalind Barr; Jenny M Kim; Robert Wasserman; Stephan A Grupp
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

7.  Interleukin 4 inhibits in vitro proliferation of leukemic and normal human B cell precursors.

Authors:  D Pandrau; S Saeland; V Duvert; I Durand; A M Manel; M T Zabot; N Philippe; J Banchereau
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

8.  Interleukin-7 is a growth factor for Sézary lymphoma cells.

Authors:  A Dalloul; L Laroche; M Bagot; M D Mossalayi; C Fourcade; D J Thacker; D E Hogge; H Merle-Béral; P Debré; C Schmitt
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

Review 9.  Role of the BCR complex in B cell development, activation, and leukemic transformation.

Authors:  Susan R Rheingold; Valerie I Brown; Junjie Fang; Jenny M Kim; Stephan A Grupp
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

10.  Interleukin-7 (IL-7)-induced proliferation of CD8+ T-chronic lymphocytic leukemia cells.

Authors:  R Yoshioka; S Shimizu; J Tachibana; Y Hirose; M Fukutoku; Y Takeuchi; S Sugai; T Takiguchi; S Konda
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.